Shares of Amneal Pharmaceuticals Inc. (AMRX) touched a new high of $9.62 yesterday, driven by its recent strong quarterly performance and an upward revision to full-year 2025 guidance.
This global pharmaceutical company develops, manufactures, markets, and distributes a diverse portfolio of essential medicines, including retail generics, injectables, biosimilars, and specialty branded pharmaceuticals. It has three reportable segments - Generics, Specialty, and AvKARE.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com